Renin angiotensin aldosterone system inhibitors/antagonists/blockers (RAASi) are a cornerstone in treatment of patients with cardiovascular diseases especially in those with heart failure (HF) due to their proven effect on surrogate and hard endpoints. Renin angiotensin aldosterone system inhibitors are also the basis in treatment of arterial hypertension, and they are furthermore indicated to reduce events and target organ damage in patients with diabetes and chronic kidney disease, where they have specific indication because of the evidence of benefit. Renin angiotensin aldosterone system inhibitor therapy, however, is associated with an increased risk of hyperkalaemia. Patients with chronic kidney disease and HF are at increased risk of hyperkalaemia and 50% of these patients experience two or
þ ) is the most abundant cation in the body (50- 75 mEqL/kg body weight). Under physiological conditions, approximately 98% of total body K þ is located in the intracellular space and only 2% in the extracellular space. Hyperkalaemia defined as serum or plasma K þ > 5 mmol/L (for K þ 1 mmol/L = 1 mEq/L) is a common electrolyte disorder that may develop due to increased K þ intake, reduced K þ excretion and shift of K þ from intracellular to extracellular space.
Food is the primary source of K þ intake with the relative amounts of K þ differing greatly between foods. The highest amounts of K þ are found in fruits, vegetables, and meat. However, a sometimes overlooked dietary K þ source comes from salt substitutes (i.e. Na þ chloride substituted by K þ chloride) and nutritional supplements. High K þ intake may cause hyperkalaemia if renal K þ excretion is impaired.
The kidneys are, under normal conditions, responsible for up to 90-95% of K þ elimination with the colon being responsible for the majority of the remaining K þ excretion. However, the colonic excretion of K þ increases when renal function worsens. In fact, in patients with end-stage renal disease faecal K þ secretion is three-fold greater as compared to patients with normal renal function. This finding suggests that the colon might assume an accessory K þ excretory role and a modest compensatory mechanism for reduced renal K þ excretion. While long-term regulation of K þ levels occurs mainly in kidneys, short-term regulation mainly occurs in skeletal muscles. Several common clinical conditions and drugs ( Table 1 ) are known to cause or aggravate hyperkalaemia. Amongst these drugs, Renin angiotensin aldosterone system inhibitors/antagonists/blockers (RAASi) are those most frequently associated with hyperkalaemia in patients with cardiovascular disease, but against this must be counter-balanced with the fact that they are among the drugs that confer the most significant survival benefit in patients with cardiovascular disease. [1] [2] [3] [4] [5] [6] [7] [8] Guidance on how best to direct the management of cardiovascular patients in the sub-acute (post-emergency) and chronic phases of hyperkalaemia is in increasing demand due to the increasing use of RAASi. This document is an expert consensus on the optimum management of hyperkalaemia in the post-emergency phase in patients with cardiovascular disease, especially in those receiving or having a compelling indication to receive RAASi.
Hyperkalaemia

K
þ levels were traditionally measured in serum from coagulated blood but are now more often measured in plasma from heparinized blood. Serum levels may be up to 1 =2 mEq/L higher than plasma levels. This is especially the case for high values. In addition, errors associated with blood sampling may also cause erroneously high K þ levels. These factors must be taken into consideration by the clinician, and must be clarified in any scientific study on hyperkalaemia. In the present document, we mostly use the expression K þ level since it is unclear in many studies, what was actually measured. The severity of hyperkalaemia can be classified as mild (>5.0 to <5.5 mEq/L) to moderate (5.5 to 6.0 mEq/L) and to severe at thresholds (>6.0 mEq/L) ( Figure 1) . The risk for the development of arrhythmic emergencies and sudden arrhythmic death in patients with hyperkalaemia is widely variable as life-threating arrhythmias may occur at different thresholds and vary between different patients. Often K þ levels up to 6 mEq/L are found in patients without any signs of arrhythmia, especially if they have chronic kidney disease, diabetes, or heart failure (HF). In these patients, hyperkalaemia is often incidentally discovered whilst performing routine blood tests. Besides, the definition based on K þ levels, hyperkalaemia can be classified as acute or chronic or recurrent according to the onset and the number of hyperkalaemia episodes experienced. Chronic or recurrent hyperkalaemia is defined as K þ levels > 5 mEq/L repetitively measured over a 1-year period. Pseudo-hyperkalaemia refers to high K þ level in the test tube without hyperkalaemia in the body. This may be caused by release of K from blood or tissue during sampling. If pseudohyperkalaemia is suspected measurement should be repeated with blood sampled appropriately or eventually taken as an arterial sample. In case of haemolysis, the clinician should consider whether it occurs in the test tube or in the body. [6] [7] [8] [9] [10] The occurrence of hyperkalaemia differs between in-and outpatients. It is present in 2-4% of the general population and in 10-55% of patients hospitalized for any cause depending on the K þ level used to define hyperkalaemia in the different studies. Both the prevalence of hyperkalaemia and risk of recurrence increase as severity and number of comorbidities increase. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] The incidence of hyperkalaemia increases with the severity of renal impairment, it is often iatrogenic, caused by concurrent drugs and nutritional/herbal supplements ( Table 1) . In clinical practice, hyperkalaemia occurs in up to 73% of patients with advanced chronic kidney disease and in up to 40% of patients with chronic HF. It leads to more frequent hospitalizations and increased mortality, especially when stringent monitoring is not performed. 3, 5, Hyperkalaemia frequently occurs in patients with cardiovascular diseases (e.g. HF, arterial hypertension, and coronary artery disease), in particular when combined with renal function impairment, diabetes, and advanced age. Hyperkalaemia may be responsible for cardiac arrhythmias leading to cardiac arrest and death, with a resulting Expert consensus document on the management of hyperkalaemia mortality rate of up to 30%. Severe hyperkalaemia is an independent predictor of all-cause and in-hospital mortality and hospitalizations.
Life-threatening hyperkalaemia requires immediate treatment with a combination of calcium carbonate and hyperosmolar sodium (if the individual has hyponatraemia) to stabilize the myocardial cell membrane; insulin w/wo glucose and/or beta adrenoceptor agonists (e.g. salbutamol) (off-label use in some EU countries) and sodium bicarbonate to transfer K þ into the cells. 17 Table 2) . Despite being recommended for use, RAASi drugs are unfortunately seldom re-instated following an episode of hyperkalaemia at or after discharge even if a different clear precipitating cause of hyperkalaemia was detected and eliminated. The most common clinical scenario is that doses of RAASi are reduced, or they are simply discontinued; this is particularly true for mineralocorticoid receptor antagonists (MRAs). Although RAASi dose reduction or discontinuation may reduce the risk of reoccurrence of hyperkalaemia, discontinuation of RAASi is associated with an increased risk of worsening of the underlying cardiovascular condition and mortality. 13, 14, [37] [38] [39] Renin angiotensin aldosterone system inhibitors and hyperkalaemia
Renin angiotensin aldosterone system inhibitors are the cornerstone of the treatment of patients with cardiovascular diseases [heart failure with reduced ejection fraction (HFrEF), arterial hypertension, coronary artery disease, myocardial infarction, left ventricular (LV) hypertrophy], with a Class IA recommendation in current clinical guidelines due to the proven reduction of mortality and morbidity in HFrEF. 16, 20, 40 Renin angiotensin aldosterone system inhibitors are the basis of the treatment of arterial hypertension and in hypertensive patients an MRA must be implemented before resistant hypertension is diagnosed. 15 Renin angiotensin aldosterone system inhibitors are also indicated to reduce events and target organ damage in patients with diabetes and chronic kidney disease where they have a specific indication because of the overwhelming evidence of benefit. 15, 17 Since RAASi increase K þ levels, RAASi-induced hyperkalaemia often limits the use of these drugs thereby offsetting their survival benefits. In hypertensive patients without risk factors for hyperkalaemia, the incidence of hyperkalaemia with RAASi monotherapy is < _2% and increases to 5% with dual RAAS inhibition and to 5-10% when dual therapy is administered in patients with HF or chronic kidney disease. 14, 31 According to current guidelines MRAs should be implemented in therapy after an ACEi (or an angiotensin II receptor blocker (ARB) in intolerant patients) has been already initiated. [15] [16] [17] In patients with chronic HFrEF, in New York Heart Association (NYHA) functional class II, and meeting specific inclusion and exclusion criteria, including an eGFR > 30 mL/min/1.73 m 2 and K þ level < 5.0 mmol/L, eplerenone was both efficacious and safe when carefully monitored, even in subgroups at high risk of developing hyperkalaemia or worsening renal function. 13 Furthermore, in the RALES trial, the benefit of spironolactone was maintained in the setting of moderate hyperkalaemia, and clinical outcomes with spironolactone were superior to placebo when K þ levels remained <6.0 mEq/L. 41 In this trial, 13 .5% and 40% of participants exhibited hyperkalaemia when treated with 25 and 50 mg daily of spironolactone. This finding suggests that limiting the maximum dose to 25 mg daily may reduce the risk of hyperkalaemia and argues against automatic Patients with cardiovascular disease and chronic kidney disease are at risk of hyperkalaemia and 50% of these patients have two or more recurrences within 1 year. [42] [43] [44] [45] Incidence rates of hyperkalaemia have been shown to be higher in HFrEF patients on MRA in the real-world setting than in clinical trials (6-12%), i.e. when they are administered to higher-risk and unselected populations which did not receive K þ level and/or creatinine monitoring. [44] [45] [46] [47] In the real-world setting, the incidence of hyperkalaemia can be as high as 50% in unselected population of patients receiving RAASi. 32, 34 Despite this evidence and guideline recommendations, K þ levels are frequently under-monitored in patients treated with RAASi. 35, 48 Therefore, quality improvement programmes are needed to improve rates of laboratory monitoring for patients initiated on MRA therapy, particularly in high-risk patients. Thresholds for the definition of the severity of hyperkalaemia differ between different classifications. This may mainly be due to different methods used to determine K þ levels. 48 Among patients with chronic kidney disease RAASi were prescribed at the target guideline recommended dose in 19% to 26% of patients, at submaximal dose in 58% to 65% of patients and were discontinued during follow-up in 14% to 16% of patients. 49 Cardio-renal adverse events/mortality and mortality occurred in 34.3% and 11.0% of patients who discontinued RAASi inhibitors, 24 .9% and 8.2% of patients on submaximal doses, and 24.9% and 4.1% of patients on maximum doses, respectively. 49 Recently, the BIOSTAT-CHF reported that only 22% of patients with HFrEF achieved the recommended treatment dose for ACEi/ ARB. 50 Reaching <50% of the recommended dose of ACEi/ARB doses was associated with an increased risk of death and/or HF hospitalization compared with patients reaching > _100%. 50 The importance of guideline adherence on prognosis has been recently highlighted by the QUALIFY global survey in 7092 patients with HFrEF. 51 In this registry good adherence to guidelines was associated with a significant prognostic benefit, the adherence score was good in 67%, moderate in 25%, and poor in 8% of patients and the proportion of patients at target dose and at > _50% of target dose was 27.9% and 63.3% for ACEi and 6.9% and 39.5% for ARBs, respectively. 51 Despite the fact that data from registries usually provide a more accurate picture than clinical trials regarding on 'real life' situations. Clinical trials, with the latter showing consistently show better treatment results or adherence to interventions, However, even registries they can also identify populations that are receiving better care compared to the general population. Indeed, a recent comparison of patients enrolled and those not enrolled in the Swedish Heart Failure Registry showed that survival was substantially higher in the registry setting, and this was most likely due to better use of RAASi drugs in registry included patients. 52 
Current guidelines and management of hyperkalaemia
Current clinical guidelines recommend that patients with chronic hyperkalaemia should be started on a low K þ diet and have to be initiated on a non-K þ sparing diuretic or if already on a diuretic, to increase the dose. [53] [54] [55] All guidelines also suggest to eliminate K þ supplements and to discontinue drugs that compromise renal function such as NSAIDs and those that may increase K þ levels such as RAASi therapy, especially MRAs ( Table 3) . The ESC Heart Failure Guidelines suggest that if a short-term cessation of K þ -retaining agents and RAASi is deemed necessary, this should be minimized and RAAS inhibitors should be carefully reintroduced as soon as possible while monitoring K þ levels. 20 As recommended by several regulatory agencies, the chronic use of SPS alone or in conjunction with sorbitol should be avoided because its prolonged use may be associated with severe gastrointestinal side effects such as bowel necrosis. 56 Sodium polystyrene sulfonate has never undergone rigorous testing in placebo-controlled clinical trials to prove its efficacy and safety for treatment of acute or chronic hyperkalaemia. 57, 59 In addition, because Na þ is the counter exchange ion in SPS, caution is advised if it is administered to patients who do not tolerate even a small increase in Na þ load (i.e. those with HF, severe hypertension, or marked oedema). 59 Here K þ binders with a different counter exchange ion (i.e. PSC) may be alternatives. 
Consensus on the implementation of renin angiotensin aldosterone system inhibitors therapies in patients with episodes of hyperkalaemia
Since RAASi therapy reduces mortality and morbidity in patients with cardiovascular disease but can increase K þ levels, therapies aimed at lowering K þ levels and enabling patients to continue RAASi therapy should be considered. Such an approach is already implemented in other fields of medicine, e.g. in cancer where symptomatic therapy is used to enable use of cancer-directed therapy (antiemetics and cytostatic drugs). The use of such an approach in patients with cardiovascular disease, who develop hyperkalaemia or borderline high K þ level under RAASi therapy may be of benefit to many including those who benefit most from RAASi therapy. Thus, the recent availability of two new effective and safe K the treatment of hyperkalaemia. 60, 61 In clinical trials, both compounds have been shown to be effective to normalize elevated K þ levels, maintain normo-kalaemia over time and prevent the recurrences of hyperkalaemia in patients with hyperkalaemia on RAASi therapy. 62, 68 Therefore, for most patients with cardiovascular disease and chronic or recurrent hyperkalaemia, RAASi therapy should be optimized whenever possible and treatment with PSC or SZC (when approved) may be initiated. In the absence of clinical guidelines and of ad hoc randomized clinical trials with hard endpoints, this consensus is based on inferred available evidence but will need to be confirmed by appropriate clinical trials. 69, 70 In patients with hyperkalaemia an evaluation should be made of the patient's diet, use of supplements, salt substitutes, and nutraceuticals that contain K þ as well as of concomitant medications that may contribute to hyperkalaemia. Expert consensus document on the management of hyperkalaemia to protect against development of hypokalaemia, which may be even more dangerous than hyperkalaemia.
In general, RAASi therapy should be started at a low dosage starting an ACEi (ARB when indicated) first and an MRA thereafter and titrated to the maximum tolerated evidence-based doses shown to reduce the risk of cardiovascular and renal events in clinical trials.
In 
